Dingzhi Huang Ph.D.

Associations and Memberships

Vice chairman of the youth committee for targeted therapy, Chinese Anti-Cancer Association,

Committee member of the Society of Lung Cancer, Chinese Anti-Cancer Association,

Committee member of the Society of Precision Medicine, Chinese Anti-Cancer Association,

Vice chairman of the youth committee for chemotherapy, Chinese Anti-Cancer Association.



Dr. Dingzhi Huang received his PhD in oncology from Peking Union Medical College in 2005. He is a Chief Physician with the Department of Thoracic Medical Oncology at Tianjin Medical University Cancer Institute and Hospital, specialized in medical treatment of thoracic carcinoma, especially for lung cancer. At present, his research focuses on translational clinical research of tumor microenvironment of lung cancer. Dr. Huang has led and participated in a number of clinical studies, undertaken one National Natural Science Foundation of China (NSFC), and one provincial and municipal science foundation. As the first or corresponding author, he has published 10 SCI papers, with the highest citation of more than 300 times. In 2018, he was selected as an outstanding talent in clinical skill of Tianjin Medical University Cancer Institute and Hospital.



[1] Wang J, Guan X, Zhang Y, Ge S, Zhang L, Li H, Wang X, Liu R, Ning T, Deng T, Zhang H, Jiang X, Ba Y, Huang D*: Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018, 49:869-83.

[2] Qin T, Huang D, Liu Z, Zhang X, Jia Y, Xian CJ, Li K: Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor-C in a mouse model of lung cancer. Cancer science 2018, 109:2469-78.

[3] Guan XW, Zhao F, Wang JY, Wang HY, Ge SH, Wang X, Zhang L, Liu R, Ba Y, Li HL, Deng T, Zhou LK, Bai M, Ning T, Zhang HY, Huang DZ*: Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes. American journal of cancer research 2017, 7:1913-25.

[4] Haiyang Zhang, Ming Bai, Ting Deng, Rui Liu, Xia Wang, Yianjun Qu, Jingjing Duan, Le Zhang, Tao Ning, Shaohua Ge, Hongli Li, Likun Zhou, Yuchen Liu, Dingzhi Huang*, Guoguang Ying*, Yi Ba*. Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. Cancer Lett. 2016;375:331-339.

[5] Haiyang Zhang, Jingjing Duan, Yanjun Qu, Ting Deng, Rui Liu, Le Zhang, Ming Bai, Jialu Li, Tao Ning, Shaohua Ge, Xia Wang, Zhenzhen Wang, Qian Fan, Hongli Li, Guoguang Ying, Dingzhi Huang*, Yi Ba*. Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer. Protein Cell. 2016;7:141-151.

[6] Huang DZ, Wang HY, Liu R, Li HL, Ge SH, Bai M, Deng T, Yao GY, Ba Y: miRNA27a Is a Biomarker for Predicting Chemosensitivity and Prognosis in Metastatic or Recurrent Gastric Cancer. Journal of cellular biochemistry 2014, 115:549-56.

[7] Huang DZ, Ba Y, Xiong JP, Xu N, Yan Z, Zhuang ZX, Yu Z, Wan HP, Zhang Y, Deng T, Zheng RS, Guo ZQ, Hu CH, Wang ML, Yu ZH, Yao Y, Meng JC: A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer 2013, 49:2995-3002.